🇺🇸 FDA
Pipeline program

SHP639 (n=60)

SHP639-101

Phase 1 small_molecule completed

Quick answer

SHP639 (n=60) for Primary Open-angle Glaucoma (POAG) is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Primary Open-angle Glaucoma (POAG)
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials